Johnson and Johnson (J&J) recently granted permission to Stop TB Partnership to distribute its generic TB drug bedaquiline (SIRTURO) to the majority of low- and middle-income countries.
A Phase 1 trial found that a freeze-dried, temperature-stable experimental tuberculosis vaccine was safe, well-tolerated and elicited robust antigen-specific serum antibody and Th1-type cellular immune responses.